Daratumumab or Active Monitoring for High-Risk Smoldering Multiple Myeloma.

已完结 10 由士多啤梨发布于 2025/10/30 10:06:50

DOI:10.1056/NEJMoa2409029
作者：Meletios A Dimopoulos,?Peter M Voorhees,?Fredrik Schjesvold,?Yael C Cohen,?Vania Hungria,?Irwindeep Sandhu,?Jindriska Lindsay,?Ross I Baker,?Kenshi Suzuki,?Hiroshi Kosugi,?Mark-David Levin,?Meral Beks
文献类型：期刊论文
补充材料：只需要正文

New England Journal of Medicine (NEJM)

Abstract：Background: Daratumumab, an anti-CD38 monoclonal antibody, has been approved for the treatment of multiple myeloma. Data are needed regarding the use of daratumumab for high-risk smoldering

应助信息

求助已完结，文件已删除 如有需求请重新发布求助一键发布

感谢使用Book学术
本站所有文献仅供个人学习和参考，请勿将文件进行传播。共同遵守网站规定和相关知识产权规定。

上一个求助:其它数据库Naturally Fractured Carbonate Reservoir Characterization: A Case Study of a Mature High-Pour Point Oil Field in Hungary 下一个求助:World ScientificTime-varying full-state constrainted USV tracking based on Fixed-time sliding mode control